Clinical Trials Directory

Trials / Completed

CompletedNCT06205407

A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma

A Single-dose, Open-label, Randomized, 2-way, Cross-over Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer From Viatris to Neolpharma, for Spironolactone/Hydrochlorothiazide Film Coated Tablets in Healthy Adult Participants Under Fasted Conditions.

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Pfizer · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

The purpose of the study is to understand how the body processes Spironolactone and Hydrochlorothiazide after taking Spironolactone and Hydrochlorothiazide film coated tablets manufactured at two sites: Viatris and Neolpharma by mouth. The study is seeking for: * Both male and female participants. * participants who must be 18 to 75 years of age. * Body Mass Index of participants should be 16 to 32 kilogram per meter squared and body weight should be more than 50 kilograms (110 pounds). About 40 participants will enter the study (20 in each group). Study consists of two periods. On Day 1 of each period, participants will receive a single amount of Spironolactone and Hydrochlorothiazide tablets. The total duration of study will be 71 days. Follow up may occur via telephone after 35 days after taking the final tablet of the study medicine.

Conditions

Interventions

TypeNameDescription
DRUGSpironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from ViatrisManufactured at Viatris
DRUGSpironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.Manufactured at Neolpharma.

Timeline

Start date
2023-12-26
Primary completion
2024-03-01
Completion
2024-03-01
First posted
2024-01-16
Last updated
2025-03-21
Results posted
2025-03-21

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06205407. Inclusion in this directory is not an endorsement.